

Original article

Prevalence of twitching motility in *Pseudomonas aeruginosa* isolated from medical facilities

— Prevalence of TM in *P. aeruginosa* isolated from medical facilities —

Yuji NAKADA Associate professor, Department of Nursing, Faculty of Nursing and Rehabilitation, Aino University

Tomoyo MATSUSHITA Graduate student of Osaka Medical College

Abstract

Pseudomonas aeruginosa is an opportunistic bacterial pathogen, the infection system of which includes the possession of type IV pili. Type IV pili-dependent twitching motility (TM) is important for attachment to the epithelium and biofilm formation. Accordingly, there is a close relationship between the expression of pili and infection through intermediate biofilm formation. However, not all isolated strains of *P. aeruginosa* carry the pili-motility function. In this study, we isolated *P. aeruginosa* strains from various medical facilities and determined the TM prevalence. A total of 27 strains were isolated from bathrooms and nursing station sinks, 52% of which possessed clear TM ability. The strength of the TM ability differed by strain, with 15% indicating a marked ability. These results support the possibility that some of *P. aeruginosa* strains isolated from medical facilities can act as causative organisms of infection.

Key words: *Pseudomonas aeruginosa*, pili, twitching motility

INTRODUCTION

Pseudomonads are prevalent opportunistic human pathogens that cause acute pneumonia, cystic fibrosis, and septicemia in immunocompromised individuals (Govan *et al.*, 1996). In addition, their natural low-level susceptibility to antimicrobial agents, accumulated resistance after exposure to various antibiotics, and the cross-resistance between agents have resulted in multi-drug resistant strains (Aloush *et al.*, 2006). In the *Pseudomonas* genus, *P. aeruginosa* (Stover CV *et al.*, 2000) is a well-known cause of pneumonia, with high rates of fatality in senior and long-term inpatients. *P. aeruginosa* is a gram-negative bacterium living in soil and aqueous environments, where it survives due to its environmental adaptations, such as its ability to use a variety of nutrients and its ability to form a biofilm through highly developed gene expression and regulation systems (Nishijyo *et al.*, 2001).

Biofilms are composed of surface-associated communities of sessile bacteria embedded in a polysaccharide matrix (Hall-Stoodley *et al.*, 2004), and their characteristic resistance to antibiotics and host immune responses compromise infection control (Drenkard E, 2003). Biofilm development has been well characterized in *P. aeruginosa*, which comprises surface attachment, microcolony formation, and differentiation into a mature antibiotic-resistant population encased in an extracellular polymeric matrix (Costerton *et al.*, 1995). In the early and multiple steps of biofilm formation, flagellar-based swimming and type IV pili-dependent twitching motility (TM) are important for attachment to abiotic surfaces and the epithelium (O'Toole *et al.*, 1998; Dorr *et al.*, 1998). As a result, there is a close relationship between pili expression and infection through intermediate biofilm formation. However, not all isolated strains of *P. aeruginosa* carry the pili-motility function, and

the distribution of TM among different strains has yet to be examined. In the present study, we performed the screening of *P. aeruginosa* in medical facilities populated by a large number of long-term inpatients, and assessed the prevalence of TM in the isolated strains.

MATERIALS AND METHODS

Bacterial strains and growth conditions

The standard strains and plasmids used are listed in Table 1. *Escherichia coli* and *P. aeruginosa* strains were respectively cultured in Luria-Bertani (LB) and nutrient yeast broth (NYB) supplemented with antibiotics when appropriate (Hass *et al.*, 1977; Sambrook *et al.*, 1989). The standard strains of *P. aeruginosa* (PAO1, ATCC33348, ATCC33350, ATCC33351, ATCC33353, ATCC33354, ATCC33356, ATCC33357, ATCC33358, ATCC33359, and ATCC33360) were isolated from patients.

DNA techniques

DNA purification, restriction enzyme analysis, and other DNA manipulations were conducted as previously described (Itoh 1997; Sambrook *et al.*, 1989). PCR was performed with KOD DNA polymerase (Toyobo Biochemicals, Japan) under the reaction conditions recommended by the supplier, and nucleotides were sequenced using an ABI3130 DNA sequencer and Big-Dye Terminator sequenc-

ing kit (Applied Biosystems, USA), as described previously (Nakada & Itoh, 2002).

Isolation of sample strains from medical facilities

Strains were collected from core hospitals with a large number of senior long-term inpatients (1,300 beds) in the Kansai region of Japan in 2007–2008. The isolated samples were obtained from nursing station sinks and bathrooms using pseudomonad-selective NAC agar plates for environmental microorganism sampling (Eiken Kagaku, Japan). After a 24-hr incubation at 37°C, the strains which formed colonies of more than 1 mm in diameter were selected for the following experiments.

Identification of isolated pseudomonads

Isolates grown on the NAC agar plates included a few other species in addition to the genus *Pseudomonas*. Therefore, amplification and detection using *oprI* and *oprL* lipoprotein genes were conducted to identify *Pseudomonas* and *P. aeruginosa* (De VD *et al.*, 1993, 1997). Positive amplification of the *oprI* gene indicated the genus *Pseudomonas*, while *oprI* and *oprL* genes identified *P. aeruginosa*. For further confirmation and species identification, the analysis of 16SrRNA gene sequences was performed. The primers used for PCR are presented in Table 2.

Sequence determination of 16SrRNA gene sequences

The nearly complete sequence (corre-

Table 1 Strains and the plasmid used in this study

Strains & plasmid	Relevant characteristics	Reference or source
Strains		
<i>P. aeruginosa</i>		
PAO1	wild type	Stover CV <i>et al.</i> 2000
ATCC33348	wild type	Veron M <i>et al.</i> 1961
ATCC33350	wild type	Veron M <i>et al.</i> 1961
ATCC33351	wild type	Veron M <i>et al.</i> 1961
ATCC33353	wild type	Veron M <i>et al.</i> 1961
ATCC33354	wild type	Veron M <i>et al.</i> 1961
ATCC33356	wild type	Veron M <i>et al.</i> 1961
ATCC33357	wild type	Veron M <i>et al.</i> 1961
ATCC33358	wild type	Veron M <i>et al.</i> 1961
ATCC33359	wild type	Veron M <i>et al.</i> 1961
ATCC33360	wild type	Veron M <i>et al.</i> 1961
<i>E. coli</i>		
DH5α	<i>F-/endA1 hsdR17 (rk-, mk+) supE44 thi-1 recA1 gyrA relA1 D(lacIZYA-argF)U169 deoR(F80dlacD(lacZ)M15)</i>	Bethesda Research Laboratories
Plasmid		
pUC118	ApR, ColE1 replicon	Vieira <i>et al.</i> 1987

Table 2 PCR primers, their target genes and annealing temperatures

Primer	Oligonucleotide sequence (5'-3')	Annealing temperature (°C)	Target and size of the expected product (bp)
SP1	ATGAACAACGTTCTGAAATTCTCTGCT	57	<i>oprI</i> , 249
SP2	CTTGCGGCTGGCTTTTCCAG		
PAL1	ATGGAAATGCTGAAATTCGGC	56	<i>oprL</i> , 504
PAL2	CTTCTTCAGCTCGACGCGACG		
UFPL	AGTTTGATCCTGGCTCAG	56	16SrRNA gene, 1490
URPL	GGTTACCTGTTACGACTT		

Table 3 TM ability of isolated and standard strains of *P. aeruginosa*

TM zone (mm)	Number of isolated strains	Number of standard strains
0~5	13	3
6~20	10	2
21~	4	6

sponding to positions 9 to 1,500 in the *E. coli* numbering system) of the 16SrRNA gene of pseudomonads was amplified by employing PCR with the conserved primers UFPL (AGTTTGATCCTGGCTCAG) and URPL (GGTTACCTGTTACGACTT) (Table 2). The amplified fragment was cloned into plasmid pUC118 at the *HincII* site to verify the nucleotides by sequencing. The sequencing primers used were UFPL, URPL, 16SF1 (5'-GCCTTCGGGTTGTAAAGCAC-3'), 16SF2 (5'-CCTTACCTACCCTTGACA-3'), 16SB1 (5'-GCGCTCGTTGCGGGACT-3'), and 16SB2 (5'-GTATTACCGCGGCTGCTG-3') (Lixia Liu, 2002). Sequence assembly was performed using ATGC Ver. 5 (Genetyx Corporation, USA).

TM assay

The isolated and standard strains of *P. aeruginosa* colonies were stab-inoculated in 2-mm-thick LB agar on an underlying Petri dish using a sterilized toothpick (Alm RA *et al.*, 1995). After incubation at 37°C for 24 hr, the zone of motility at the agar/Petri dish interface (TM zone) was measured (Fig. 1).

Results

Bacterial isolation and identification of pseudomonads

A total of 83 strains were obtained from nursing station sinks and bathrooms in the examined medical facilities. Through the *oprI* target PCR assay, 73 isolates were identified as *Pseudomonas*, while a further *oprL* target PCR assay revealed 27 isolates of *P. aeruginosa*. The isolated *Pseudomonas* strains were also

examined using 16SrRNA gene sequencing, revealing three typical strains: *P. aeruginosa*, *P. alcaligenes*, and *P. mendocina*.

TM prevalence in the isolated *P. aeruginosa* strains

We examined the TM ability of all strains identified as *P. aeruginosa*. As shown in Table 3, 14 strains showed a clear TM zone (more than 6 mm), with the overall TM rate being 52%.

TM prevalence in standard strains of *P. aeruginosa*

The TM ability of 11 standard strains was then determined. As shown in Table 3, 8 strains showed a clear TM zone, with the overall TM rate being 73%.

DISCUSSION

In this investigation, we surveyed nursing station sinks and bathrooms in medical facilities populated by a large number of senior long-term inpatients for strains of the genus *Pseudomonas*. The dominant isolated strains were identified as *P. aeruginosa*, *P. mendocina*, and *P. alcaligenes*, all of which are known to be opportunistic pathogens. Due to their source, they are also believed to be causative organisms of nosocomial infection. The main investigations in the past involved detection and antibiotic sensitivity tests of bacteria found on inpatients, healthcare workers, visitors, and in medical facilities. However, few close pathogenic factor investigations of resident environmental flora in medical facilities have been reported.

The isolated and identified *Pseudomonas* strains (especially *P. aeruginosa*) this time are all causative bacteria of opportunistic infections, and, thus, analysis of the pathogenic factors is particularly significant. One pathogenic factor of *P. aeruginosa* is the possession of pili, which are involved in biofilm formation and are thought to play an important role in human infection (George *et al.*, 1998). The TM ability resulting from type IV pili varies by strain, and the biogenesis and function of type IV pili are controlled by a large number of genes, almost 40 of which have been identified in *P. aeruginosa* (Jhon SM, 2002). Strains with defective pili or a lack of expression do not show apparent TM. Moreover, during colonization and multiplication on human tissue, strains showing high TM ability are more likely to cause infection (George *et al.*, 1998; Maria-Cristina *et al.*, 1994).

In the present study, we therefore focused on pili motility, revealing that about half of the medical facility-derived *P. aeruginosa* strains possessed clear TM ability. Three-quarters of the standard *P. aeruginosa* strains isolated from patients possessed clear TM ability. Furthermore, approximately 15% of the medical facility-derived strains and more than half of the standard strains isolated from patients showed a particularly marked TM ability (more than a 21-mm TM zone). These results support the possibility that the strains exhibiting high TM ability are more likely to cause infection (George *et al.*, 1998; Maria-Cristina *et al.*, 1994). Although TM ability is only re-

lated to attachment to the epithelium, we should be aware that a marked TM ability is showing by strains in medical facilities. In the future, we plan to investigate the relationship between pili expression in *P. aeruginosa* and the presence of long-term resident in medical facilities.

ACKNOWLEDGEMENTS

We would like to thank Y. Fukuda and A. Fujiwara for their cooperation during the present survey. This work was supported in part by a grant-in-aid for young scientists (B) from the Japan Society for Promotion of Science to Y. N. (18790315).

REFERENCES

- Alm RA, Mattick JS: Identification of a gene, pilV, required for type 4 fimbrial biogenesis in *Pseudomonas aeruginosa*, whose product possesses a pre-pilin-like leader sequence. *Mol Microbiol* 16: 485-96, 1995
- Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y: Multidrug-resistant *Pseudomonas aeruginosa*: risk factors and clinical impact. *Antimicrob Agents Chemother* 50: 43-8, 2006
- Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM: Microbial biofilms. *Annu Rev Microbiol* 49: 711-745, 2005
- De VD, Lim A Jr, De VP, Sarniguet A, Kersters K, Cornelis P: Detection of the outer membrane lipoprotein I and its gene in fluorescent and non-fluorescent pseudomonads: implications for taxonomy and diagnosis. *J Gen Microbiol* 139: 2215-23, 1993
- De VD, Lim A Jr, Pirnay JP, Struelens M, Vandenvelde C, Duinslaeger L, et al: Direct detection and identification of *Pseudomonas aeruginosa* in clinical samples such as skin biopsy specimens and excretions by multiplex PCR based on two outer membrane lipoprotein genes, *oprI* and *oprL*. *J Clin Microbiol*. 35: 1295-1299, 1997
- Dorr J, Hurek T, Reinhold-Hurek B: Type IV pili are involved in plant-microbe and fungus-microbe interactions. *Mol Microbiol* 30: 7-17, 1998




Fig. 1 Results of the TM assay with isolated and standard *P. aeruginosa* strains
 A: TM assay of ATCC33358. TM zone=29mm.
 B: TM assay of ATCC33356. TM zone=0mm.

- Drenkard E: Antimicrobial resistance of *Pseudomonas aeruginosa* biofilms. *Microbes Infect* 5: 1213-9, 2003
- George A, O'Toole, Roberto K: Flagellar and twitching motility are necessary for *Pseudomonas aeruginosa* biofilm development. *Mol Microbiol* 30: 295-304, 1998
- Govan JR, Deretic V: Microbial pathogenesis in cystic fibrosis: mucoid *Pseudomonas aeruginosa* and *Burkholderia cepacia*. *Microbiol Rev* 60: 539-574, 1996
- Hall-Stoodley L, Costerton JW, Stoodley P: Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol* 2: 95-108, 2004
- Hass D, Hollway BW, Schambeck A, Leisinger T: The genetic organism of arginine biosynthesis in *Pseudomonas aeruginosa*. *Mol Gen Genet* 154: 7-22, 1977
- Itoh Y: Cloning and characterization of the *aru* genes encoding enzymes of the catabolic arginine succinyltransferase pathway in *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 179: 7280-7290, 1997
- John SM: Type IV pili and twitching motility. *Ann Rev Microbiol* 56: 289-314, 2002
- Lanyi B: Serological Properties of *Pseudomonas aeruginosa*. I. Group specific somatic antigens. *Acta. Microbiol Acad Sci Hung* 13: 295-318, 1967
- Lixia L, Tom C, Jane LB, Paul WW, Terrence LS, John JL: Ribosomal DNA-directed PCR for identification of *Achromobacter* (*Alcaligenes*) *xylosoxidans* recovered from sputum samples from cystic fibrosis patients. *J Clin Microbiol* 40: 1210-1213, 2002
- Maria-Cristina P, Alessandra MS, Silvia Helena MP, Michelle PC, Odile B: *Pseudomonas aeruginosa* selective adherence to and entry into human endothelial cells. *Infect Immun* 62: 5456-5463, 1994
- Meitert T: Contribution a l'etude de la structure antigenique des *Pseudomonas aeruginosa*. *Arch. Roum. Pathol. Exp Microbiol* 3:679-688, 1964
- Nakada Y, Itoh Y: Characterization and regulation of the *gbuA* gene, encoding guanidinobutyrase in the arginine dehydrogenase pathway of *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 184: 3377-3384, 2002
- Nishijyo T, Hass D, Itoh Y: The *cbrA-cbrB* two component regulatory system controls the utilization of multiple carbon and nitrogen sources in *Pseudomonas aeruginosa*. *Mol Microbiol* 40: 917-931, 2001
- O'Toole GA, Kolter R: Flagellar and twitching motility are necessary for *Pseudomonas aeruginosa* biofilm development. *Mol Microbiol* 30: 295-304, 1998
- Sambrook J, Fritsch EF, Maniatis T: *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y. 1989
- Stover CV, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, et al.: Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature* 406: 959-964, 2000
- Veron M: Sur l'agglutination des *Pseudomonas aeruginosa*; subdivision des groupes antigeniques O: 2 et O: 5. *Ann Inst Pasteur Paris* 101: 456-460, 1961
- Vieira J, Messing J: Production of single-stranded plasmid DNA. *Methods Enzymol* 153: 3-11, 1987